Green Cross LabCell
107, Ihyeon-ro 30beon-gil, Yongin-si, Gyeonggi-do, 16924, South Korea
Overview
GC Green Cross Their goal is to contribute to the healthy life of mankind and become a global leader in the healthcare industry. Recent advances in biotechnology have become a good foundation for achieving their goals. The paradigm of medicine is changing. They are shifting from traditional medicines and synthetic medicines to biopharmaceutical development. GC Green Cross Cellular gene therapy, which is the main pipeline of LAPSEL, is expected to enable the treatment of rare and intractable diseases as well as cancer, because of the fundamental treatment of diseases at the gene and cell level. In particular, successful cases such as approval of the first immunotherapeutic drug (CAR-T) in 2017 and the approval of the first gene therapy (Luxturna) were epoch-making events that transformed the expectations they had in mind into reality. Is added.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
Investment portfolio
- Artiva Biotherapeutics
Participated · Series B · Feb 2021
Artiva is an oncology-focused biopharmaceutical company building primary allogeneic NK cell therapies optimized for anti-tumor activity and safety. Its platform supports large-scale production and cryopreservation of off-the-shelf NK cell therapies and includes proprietary CAR-NK and NK-specific gene-editing technologies. The pipeline includes AB-101, an ADCC-enhancer NK-cell therapy in a Phase 1/2 trial in combination with rituximab for relapsed or refractory B-cell lymphomas. Its CAR-NK programs include AB-201 (HER2-specific for HER2+ solid tumors) and AB-202 (CD19-specific for B-cell malignancies), with plans to enter clinical trials in 2022 under a master license and option agreement with GC LabCell. Artiva has entered therapeutic collaborations or license agreements with Merck and Affimed and leverages cell-expansion and engineering technology developed by corporate partner GC LabCell. The company is headquartered in San Diego and emphasizes a "manufacturing first" strategy to deliver immediately accessible cell therapies. Artiva is an oncology company focused on developing and commercializing allogeneic, off-the-shelf NK cell and CAR-NK therapies. Its initial pipeline includes AB-101 (a universal NK cell therapy intended for use with monoclonal antibodies), AB-201 (a HER2-specific CAR-NK for HER2+ solid tumors), and AB-202 (a CD19-specific CAR-NK for CD19+ B-cell malignancies). The company emphasizes large-scale production and effective cryopreservation to enable high and repeat dosing, and it leverages a manufacturing and engineering platform optimized for expansion, activation, engineering, and NK-specific gene editing. Artiva has exclusive ex-Asia-Pacific license agreements with GC LabCell covering core manufacturing and CAR technology and an option to license additional research candidates under a Joint Steering Committee. The company plans to enter the clinic this year with AB-101 in combination with an anti-CD20 monoclonal antibody to treat relapsed refractory B-cell lymphoma. Artiva is headquartered in San Diego and will use its new financing to advance its universal NK cell and CAR-NK product candidates.
Team
No current team members are available.